Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Environmental Toxicology and Chemistry|June 29, 2021
Perfluorooctane Sulfonate in US Ambient Surface Waters: A Review of Occurrence in Aquatic Environments and Comparison to Global ConcentrationsAmanda L Jarvis, James R Justice, Michael C Elias, et al.
Circulation Research|October 1, 1979
Presence of negative inotropic agents in canine plasma during positive end-expiratory pressureG A Grindlinger, J Manny, R Justice, et al.
The Oncologist|September 24, 2005
Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapyRoger Waltzman, Christopher Croot, Glen R Justice, et al.
Oncology|January 1, 1975
Methotrexate with leucovorin rescue in the treatment of gynecologic malignancies. Preliminary reportM P Corder, L F Hively, W H Stone, et al.
Clinical Pharmacology and Therapeutics|April 1, 1977
Leucovorin in combination chemotherapy of breast cancerM P Corder, R F Sheets, W H Stone, et al.
The Oncologist|October 27, 2007
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemiaVeena Charu, Bruce Saidman, Ali Ben-Jacob, et al.
Environmental Toxicology and Chemistry|July 21, 2021
Direct and Delayed Mortality of Ceriodaphnia dubia and Rainbow Trout Following Time-Varying Acute Exposures to ZincChristopher A Mebane, Christopher D Ivey, Ning Wang, et al.
American Journal of Clinical Oncology|September 1, 2007
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial resultsYehuda Z Patt, Fa-Chyi Lee, James E Liebmann, et al.
Clinical Pharmacology and Therapeutics|February 4, 2014
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancerJ Wang, P Song, S Schrieber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2001
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphomaA Tulpule, M U Rarick, J Kolitz, et al.
Pageof 3